You are here: Home » Companies » News
Business Standard

Pharma majors named in clinical trial death list

Companies say they follow global standards in India as well

Sushmi Dey  |  New Delhi 

Drug majors such as Novartis, Pfizer, Bayer Healthcare, Bristol Mayer Squibb, Sun Pharmaceutical and Dr Reddy’s Laboratories were allegedly involved in clinical trials in which 438 persons died in 2011, according to confidential government data reviewed by Business Standard.

While the argue they follow the global standards, experts point at the absence of sound regulations as the main culprit. Although the number of deaths in clinical trials has been growing through the years, it fell in 2011 from the previous year mainly because of flat growth in the clinical research market in India.

Data available with the office of the Drugs Controller General of India (DCGI) for 2011 show 57 deaths during clinical trials conducted by Novartis, 32 in trials by Quintiles, 20 each in the case of Pfizer and Bayer, 19 for Bristol Mayer Squibb and 10 for MSD Pharmaceutical.

Deaths Company
57 Novartis
32 Quintiles Technologies
20 Bayer
20 Pfizer
19 Bristol Mayer Squibb India
10 MSD Pharmaceutical
9 Sun Pharma
3 Jubilant Clinsys
3 Sanofi Aventis
1 Dr Reddy’s Laboratories
Source: Drugs Controller General of India  

Among domestic companies, nine persons allegedly died during the clinical trials of drugs developed by Sun Pharma, three in trials by Jubilant Clinsys and one in the case of Dr Reddy’s Labs. Jubilant has, however, said there were no deaths reported in 2011 that could be attributed to participation in clinical trials conducted by it.

Most other pharma argue while trials are conducted on patients suffering from serious diseases with limited or no treatment options, it is inappropriate to blame deaths on clinical trials.

“... patients who participate in clinical trials are by definition those who already have a pre-existing medical condition, which could be mild or serious, acute or chronic. Therefore, the death of a patient in a clinical trial could occur due to a variety of reasons, including those unrelated to the trial,” says Shoibal Mukherjee, chief medical officer, Quintiles India, and head, Asia Medical Sciences Group. Quintiles is a leading US-based clinical research organisation (CRO), which conducts clinical studies on behalf of pharma

According to Novartis and MSD India, there have been no deaths due to drugs during clinical trials conducted by them in 2011. Dr Reddy’s Labs says though there was one mortality reported in a trial in 2011, it was not related to the study drug.

Sun Pharma said its trial was on advanced breast cancer patients, in whom the disease had progressed to the terminal stage. “In all cases, compensation has been paid and one is under process,” it said.

According to submissions by the government in the Parliament, despite 668 deaths during clinical trials in 2010, compensation was paid in only 22 cases, that too mostly as low as Rs 1.5 lakh. Bayer, currently conducting 600 clinical trials worldwide, says it adheres to globally harmonised standards.

Experts indicate flimsy regulations are resulting in deaths during clinical trials. “In India, clinical trials can be conducted anywhere with a medical supervision. There are no minimum criteria for a trial site. Even a doctor in his private clinic is eligible to do a trial,” says Anoop Mishra, chairman, Fortis-C-DOC centre for diabetes and metabolic diseases.

According to a medical practitioner in a hospital, to undertake trials, companies often look for doctors who can quickly get more patients for their drug to be tested and complete the study faster. Most pharma companies generally hire a CRO to conduct trials for them, which in turn enrolls doctors. Some drug makers directly approach doctors to conduct trials.

Many companies are learnt to be paying hefty sums to doctors for trials. “The amount varies depending on the company, the drug and the trial duration,” a medical practitioner said.

While companies claim they seek ethics committee approvals for each participating site, experts point towards the lack of credibility attached to these panels. According to Sanofi Aventis, which reported three deaths in trials where the treating physicians felt it ‘could’ have been due to the drug itself, any death, irrespective of its cause, is reported to health agencies and to the concerned ethics committee for review.

Recently, the Supreme Court had expressed concerns over allegedly illegal clinical trials. However, according to a Pfizer spokesperson, standards applicable to trials in India are no different from those in the US, the EU or elsewhere.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, July 24 2012. 00:01 IST